GLUE on Nasdaq

Monte Rosa Therapeutics

Biotechnology company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Atara Biotherapeutics, Inc., Acorda Therapeutics or Agenus, or pick any stock.

  • TickerGLUE on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersBoston, Massachusetts1
  • Websitewww.monterosatx.com
  • Incorporated inDE3
  • Business address321 Harrison Avenue, Suite 900, Boston, Ma 021183
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome. MGDs function by inducing the engagement of an E3 ligase, such as cereblon, with defined structural features on surfaces of target proteins. These target proteins are also referred to as neosubstrates. The E3 ligase then tags the target protein for degradation by adding a molecular mark known as ubiquitin. We believe our MGDs provide significant advantages over existing therapeutic modalities, including other protein degradation approaches.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-43.8%Operating margin5
-31.2%Net margin6
63.5%Revenue growth, 20255
-16.6%Return on equity5
-$27.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢$141.5M
  • Income tax1¢$1.1M

Out of $123.7M in revenue.56 The company lost money this year.

Financial statements

Revenue75$123.7M in 2025
0$50.0M$100.0M$150.0M2023: $0$020232024: $75.6M$75.6M20242025: $123.7M$123.7M2025+64%
Operating income891075-$54.2M in 2025+94% since 2020
-$150.0M-$100.0M-$50.0M02020: -$28.0M-$28.0M20202021: -$72.9M-$72.9M2021+160%2022: -$112.4M-$112.4M2022+54%2023: -$143.3M-$143.3M2023+28%2024: -$81.1M-$81.1M2024−43%2025: -$54.2M-$54.2M2025−33%
Net income8910756-$38.6M in 2025+8% since 2020
-$150.0M-$100.0M-$50.0M02020: -$35.9M-$35.9M20202021: -$74.0M-$74.0M2021+106%2022: -$108.5M-$108.5M2022+47%2023: -$135.4M-$135.4M2023+25%2024: -$72.7M-$72.7M2024−46%2025: -$38.6M-$38.6M2025−47%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Collaboration revenue$123.7M$75.6M
Research and development$141.5M$121.6M
General and administrative$36.4M$35.2M
Total operating expenses$177.9M$156.7M
Loss from operations-$54.2M-$81.1M
Interest income$12.9M$10.6M
Foreign currency exchange gain, net$1.5M$416.0K
Gain on disposal of fixed assets$59.0K$0
Total other income$14.5M$11.0M
Net loss before income taxes-$39.7M-$70.1M
Income tax benefit (provision)$1.1M-$2.6M
Net loss-$38.6M-$72.7M
Net loss per share attributable to common stockholders - basic-$0-$1
Net loss per share attributable to common stockholders - diluted-$0-$1
Weighted-average number of common shares used in computing net loss per share - basic83.1M shares73.9M shares
Weighted-average number of common shares used in computing net loss per share - diluted83.1M shares73.9M shares
Provision for pension benefit obligation-$518.0K-$802.0K
Unrealized gain on available-for-sale securities$47.0K$170.0K
Comprehensive loss-$39.1M-$73.3M

Compare Monte Rosa Therapeutics with another company

Leadership

Who has led Monte Rosa Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Markus Warmuth2022–now

President

  1. Markus Warmuth2022–now

Chief financial officer

  1. Ajim Tamboli2021–2023

Chief operating officer

  1. Jennifer Champoux2024–now
2025
Board members and other officers (21)

Former names

  • Monte Rosa Therapeutics, Inc.Sep 29, 2020 to Oct 6, 20263

Timeline

  1. Mar 2, 2022New chief executive Markus Warmuth becomes CEO12
  2. Jun 2021Went public Listed on NASDAQ1

Filings

313 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 117 insider forms, 54 large holders, 72 other. The latest 20:

  1. Oct 6, 20264 EDGAR
  2. Oct 1, 20268-K EDGAR
  3. Sep 8, 20268-K EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G EDGAR
  6. Aug 6, 202610-Q EDGAR
  7. Aug 6, 20268-K EDGAR
  8. Jul 17, 20264 EDGAR
  9. Jul 16, 2026144 EDGAR
  10. Jul 16, 20264 EDGAR
  11. Jul 15, 2026144 EDGAR
  12. Jul 8, 2026SCHEDULE 13G/A EDGAR
  13. Jul 7, 20264 EDGAR
  14. Jul 6, 20264 EDGAR
  15. Jul 6, 2026SCHEDULE 13D/A EDGAR
  16. Jul 1, 20264 EDGAR
  17. Jun 30, 2026144 EDGAR
  18. Jun 30, 20264 EDGAR
  19. Jun 30, 20264 EDGAR
  20. Jun 29, 2026144 EDGAR

The 313 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 1 buys and 41 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 16, 2026Warmuth MarkusPresident & CEOSale9,500$23.18$220.2KForm 4
Jul 15, 2026Champoux JenniferChief Operating OfficerSale4,351$23.38$101.7KForm 4
Jul 6, 2026Townson SharonChief Scientific OfficerSale6,000$23.31$139.9KForm 4
Jun 30, 2026Janku FilipChief Medical OfficerSale5,407$24.50$132.5KForm 4
Jun 29, 2026Janku FilipChief Medical OfficerSale6,000$22.95$137.7KForm 4
Jun 29, 2026Manning Anthony M.DirectorSale10,000$23.11$231.1KForm 4
Jun 24, 2026Janku FilipChief Medical OfficerSale30,000$21.42$642.6KForm 4
Jun 23, 2026Janku FilipChief Medical OfficerSale11,845$20.22$239.5KForm 4
Jun 23, 2026Townson SharonChief Scientific OfficerSale3,000$20.00$60.0KForm 4
Jun 23, 2026Champoux JenniferChief Operating OfficerSale2,175$20.00$43.5KForm 4
Jun 17, 2026Champoux JenniferChief Operating OfficerSale2,176$19.00$41.3KForm 4
Jun 17, 2026Townson SharonChief Scientific OfficerSale3,000$19.00$57.0KForm 4
Jun 1, 2026Warmuth MarkusPresident & CEOSale5,466$19.44$106.2KForm 4
May 29, 2026Townson SharonChief Scientific OfficerSale6,000$19.87$119.2KForm 4
May 27, 2026Champoux JenniferChief Operating OfficerSale2,175$20.00$43.5KForm 4
May 22, 2026Champoux JenniferChief Operating OfficerSale2,176$19.00$41.3KForm 4
May 21, 2026Manning Anthony M.DirectorSale10,000$18.01$180.1KForm 4
May 1, 2026Warmuth MarkusPresident & CEOSale5,467$18.92$103.4KForm 4
Apr 14, 2026Warmuth MarkusPresident & CEOSale8,000$17.64$141.1KForm 4
Apr 9, 2026Nickson PhilipChief Business & Legal OfficerSale5,845$17.69$103.4KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
NEA Management Company, LLC7,692,298$186.2M11.7%No change
BlackRock, Inc.6,843,087$165.6M0.0%+1,205,403
TCG Crossover Management, LLC4,622,151$111.9M2.7%No change
Vestal Point Capital, LP4,600,000$111.3M2.6%+996,535
Bvf Inc/il4,460,886$108.0M2.8%No change
Baker Bros. Advisors LP4,345,736$105.2M0.5%No change
State Street Corp3,731,416$90.3M0.0%+377,436
Montanova Capital, LLC3,549,539$85.9M1.8%−677,270
Vanguard Capital Management LLC3,412,927$82.6M0.0%+312,682
Versant Venture Management, LLC3,180,780$77.0M47.3%No change
Braidwell LP2,451,562$59.3M2.3%−755,012
Geode Capital Management, LLC1,864,113$45.1M0.0%+323,301
American Century Companies Inc1,622,846$39.3M0.0%−1,186,801
Marshall Wace, Llp1,593,600$38.6M0.0%+160,448
Aisling Capital Management LP1,555,664$37.6M8.0%No change
Nantahala Capital Management, LLC1,303,986$31.6M1.0%+651,993
Bellevue Group AG1,190,000$28.8M0.6%−60,000
Dimensional Fund Advisors LP1,177,488$28.5M0.0%+136,116
Mpm Bioimpact LLC1,161,081$28.1M1.7%−15,847
Silverarc Capital Management, LLC1,108,295$26.8M3.0%−893,745
Jupiter Topco LLC1,072,494$26.0M0.0%New
Frazier Life Sciences Management, L.P.1,000,000$24.2M0.5%No change
Goldman Sachs Group Inc998,253$24.2M0.0%−3,274
Woodline Partners LP962,884$23.3M0.1%+888,388
Fmr LLC934,414$22.6M0.0%−89,890

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48